KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Share-based Compensation (2016 - 2025)

NovoCure's Share-based Compensation history spans 12 years, with the latest figure at $19.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 68.42% year-over-year to $19.8 million; the TTM value through Dec 2025 reached $104.8 million, down 34.49%, while the annual FY2025 figure was $104.8 million, 34.49% down from the prior year.
  • Share-based Compensation for Q4 2025 was $19.8 million at NovoCure, down from $29.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $62.8 million in Q4 2024 and bottomed at $17.4 million in Q4 2023.
  • The 5-year median for Share-based Compensation is $27.1 million (2021), against an average of $29.1 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 259.89% in 2024 before it crashed 68.42% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $22.4 million in 2021, then surged by 32.97% to $29.8 million in 2022, then tumbled by 41.45% to $17.4 million in 2023, then surged by 259.89% to $62.8 million in 2024, then plummeted by 68.42% to $19.8 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Share-based Compensation are $19.8 million (Q4 2025), $29.3 million (Q3 2025), and $26.1 million (Q2 2025).